Shankar Musunuri has spent time in both the pharmaceutical world and the biotech arena – after 15 years at Pfizer (NYSE:PFE), he went on to launch several biotech start-ups. As co-founder, chairman & chief executive of Ocugen, he is looking to bring eye disease products to the patients that big pharma’s drugs have left out. “There’s […]
Roche
First test to screen blood donations for Zika virus wins FDA nod
The FDA today approved Roche Molecular System‘s (OTC:RHHBY) cobas Zika test, which detects Zika virus RNA in plasma specimens collected from volunteer blood donors and living organ donors. The test is designed to be used by blood collection establishments to detect Zika virus in blood donations – not for the diagnosis of Zika virus infection […]
UK warns about alarm failure for Roche’s insulin pumps
The UK’s Medicines and Healthcare products Regulatory Agency issued a medical device alert for Roche‘s (OTC:RHHBY) Accu-Check Insight insulin pumps today, warning that the device’s audible and vibration alarms may not function. If a user doesn’t see the notification message on the pump and can’t hear or feel an alarm, it could lead to hyperglycemia, […]
Novartis CEO departs, leaving corner office to Harvard doc
Novartis‘ (NYSE:NVS) chief executive Joseph Jimenez is slated to leave his post next February, the drugmaker reported over the weekend. The CEO’s surprise departure leaves the corner office to Dr. Vasant Narasimhan, who currently serves as the company’s CMO and global head of drug development. The move comes just days after Novartis won FDA approval for […]
House Dems launch MS drug pricing probe
Democrats from the House Committee on Oversight and Government Reform have sent letters to seven drugmakers as part of an investigation into why prices for multiple sclerosis drugs have nearly quadrupled since 2004. Reps. Elijah Cummings (D-Md.) and Peter Welch (D.-Mass) penned inquiries to Bayer (ETR:BAYN), Biogen (NSDQ:BIIB), EMD Serono, Novartis (NYSE:NVS), Roche (OTC:RHHBY), Sanofi Aventis (NYSE:SNY) and Teva Pharmaceuticals (NYSE:TEVA). […]
Roche, Mimetas develop “gut-on-a-chip” tech for drug-testing
Mimetas said today that it collaborated with Roche (OTC:RHHBY) to develop an organ-on-a-chip system that is designed to evaluate intestinal permeability in 3D gut tubules following exposure to drug compounds. The results of the collaboration were published in Nature Communications. The researchers reported that the intestinal tubules were leak-tight after just four days in culture and […]
Roche taps Accenture’s analytics tech for digital diabetes management
Accenture (NYSE:ACN) said today that it inked a five-year deal with Roche (OTC:RHHBY) to incorporate its analytics platform into Roche’s digital diabetes management system. According to the deal, Roche’s new digital “diabetes ecosystem” will be built on the Accenture Intelligent Patient Platform. The system reportedly allows Roche to collect and analyze data from diabetes patients in […]
Senseonics inks artificial pancreas deal with Roche, TypeZero Technologies
Senseonics (NYSE:SENS) said today that it inked a collaboration with TypeZero Technologies and Roche (OTC:RHHBY) Diabetes Care to develop an automated insulin delivery system. The deal is part of an NIH-funded effort to test artificial pancreas systems. The trial is slated to integrate Senseonic’s Eversense glucose monitor, TypeZero’s inControl AP algorithms and Roche’s Accu-Chek Insight insulin pump. […]
Roche’s prospects clouded by clinical flops
(Reuters) — A run of disappointing drug trials at Roche (OTC:RHHBY) has left analysts suggesting the view from its new 41-story office building in Basel has become more clouded, with little chance of management now upgrading its growth forecast next week, when it reports first-half earnings. Moreover, the first of a threatened flood of biosimilar […]
Roche buys mySugr diabetes app
Swiss drugmaker Roche (PINK:RHHBY) said today that it bought diabetes management platform mySugr for an undisclosed price. The 2 companies have worked together since 2014. mySugr’s digital tech enables users to track things like their blood sugar, diabetes medications and physical activity. Roche’s diabetes diagnostic biz has recently faced pricing pressure, bringing about rumors that it […]
